The initial public offering of Sudeep Pharma continued to see strong investor interest during its second day of public bidding, November 24. The maiden issue of the Vadodara-based company has been subscribed more than 5 times its offer size on Day 2.
The IPO of the technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries, received bids for nearly 5.38 crore shares, as against an offer size of nearly 1.06 crore shares, according to data on NSE.
Non Institutional Investors (NII) have booked the portion reserved for them 12 times, while retail investors subscribed their allotted quota nearly 5 times so far. Qualified Institutional Buyers (QIB) have subscribed 13 percent of the portion kept for them.
Sudeep Pharma GMP:
Ahead of listing, the unlisted shares of the company were trading with 16.86 percent grey market premium (GMP) over the IPO price, according to data on Investorgain. Although the GMP has fallen from the 20.40 percent quoted by the site on November 23, it still indicates a decent listing for the pharma player.
According to IPO Watch, the unlisted shares of the company were trading with 19.39 percent GMP over the issue price.
About Sudeep Pharma IPO:
Sudeep Pharma launched its IPO to raise Rs 895 crore through a fresh issue of shares worth Rs 95 crore and an offer-for-sale (OFS) of 1.3 crore shares worth Rs 800 crore by existing promoters. The price band for the IPO has been set at Rs 563-593 per share.
The IPO will remain open for public bidding between November 21 and November 25. Retail investors can bid for a minimum of 25 shares, requiring an investment of Rs 14,825 at the upper price band, and in multiples thereafter. The allotments will likely be finalized by November 26, and the shares are scheduled to be listed on stock exchanges on November 28.
Sudeep Pharma aims to use Rs 75.81 crore from the fresh issue proceeds for capital expenditure towards procurement of machinery for its production line located at Nandesari Facility 1, Gujarat and the remained for general corporate purposes.
Should you apply for Sudeep Pharma IPO?
Investors may consider the IPO as a potential long-term investment opportunity, Master Capital Services said in its IPO note. The brokerage noted that India’s food and nutritional ingredients market is rapidly expanding, driven by increasing health awareness, a growing population, and rising disposable incomes.
“In 2024, India’s demand for food ingredients is estimated to be around $22 billion. The market is expected to grow at a CAGR of 8.1% between 2024 to 2029, with demand reaching $32 billion in 2029. In India, vitamins and minerals are integral components of dietary supplements, often recommended by healthcare professionals to complement treatment for a variety of health conditions, ranging from mild to chronic illnesses. The Vitamins and Minerals market in India, currently valued at $2.1 billion in 2024, is set for significant growth. Forecasts predict robust growth at a CAGR of 8% from 2024 to 2029, with the market expected to reach around $3.0 billion by 2029,” it said.
“The domestic pharmaceutical industry is projected to reach $130 billion by 2030 and $450 billion by 2047. India’s food and nutritional ingredients market, valued at $22 billion in 2024, is expanding rapidly on the back of rising health awareness, urbanization, and a growing middle-income population. The sector is expected to grow at a CAGR of 8.1% to reach $32 billion by 2029. Sudeep Pharma Ltd is strategically positioned to capitalize on this rapid expansion across the Pharmaceutical, Food, Nutrition and Specialty ingredients markets,” it added.
Master Capital Services added that with a technology-driven manufacturing ecosystem, in-house process capabilities and a diversified portfolio of over 100 products, Sudeep Pharma is well aligned with the sector’s evolving needs.
The Rs 268-crore anchor book and approximately 19–20 percent GMP for Sudeep Pharma's IPO send strong signals about investor confidence in the company's specialty ingredient business, said Siddharth Maurya, Founder & Managing Director, Vibhavangal Anukulakara. "This is further reflected in its long-term ambition, with plans to utilize ₹95 crore of fresh capital raised towards capacity expansion. Still, I think what's really worrisome are the risks- over 20% of its sales comes from just a few customers, its working capital cycle has ballooned. For long-term investors, this can be an attractive play, but only if Sudeep de-risks its customer concentration and scales working capital efficiently," he added.
Sudeep Pharma is commanding a premium as it has delivered steady revenue growth over the last 3 years, with high EBITDA margins around mid-20s, which is higher than many peers in the specialty pharma-ingredients space, said Shravan Shetty, Managing Director, Primus Partners. "With a customer base across 70 countries, and exports forming a significant share of revenues - they have a strong level of product and geographic diversification," he said.
"Given that there is OFS, expect P/E dilution which makes the stock less attractive post dilution. The outlook would be positive long term," he added.
Follow all IPO news here.
Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
